Selecta Biosciences Presents Positive New Data from Ongoing Phase 2 Trial of SEL-212, in Development for Chronic Severe Gout, at PANLAR 2018 Congress 3-month Phase 2 data indicate SEL-212 (SVP-Rapamycin + pegsiticase) product profile may provide better and more sustained … Continued
Twist Bioscience Completes $50 Million Financing to Fuel Advancement of Digital Storage in DNA and Drug Discovery Twist Bioscience Corporation, a company enabling customers to succeed through its offering of high-quality synthetic DNA, today announced the completion of a private … Continued
ARMO BioSciences Enrolls First Patient in the CYPRESS 2 Trial Evaluating AM0010 in Non-Small Cell Lung Cancer ARMO BioSciences, Inc. (Nasdaq:ARMO), a late-stage immuno-oncology company, today announced enrollment of its first patient in CYPRESS 2, a randomized Phase 2b trial designed … Continued
ARMO BioSciences Announces Positive Outcome of First Interim Analysis in SEQUOIA Phase 3 Pancreatic Cancer Study ARMO BioSciences, Inc. (Nasdaq:ARMO), a late-stage immuno-oncology company, today announced the completion of the first interim analysis in its Phase 3 SEQUOIA study in patients … Continued
Selecta Biosciences Announces First Patient Dosed in Phase 1 Trial of SVP-Rapamycin and LMB-100 Combination Therapy in Mesothelioma Selecta Biosciences, Inc. (Nasdaq:SELB), a clinical-stage biopharmaceutical company focused on unlocking the full potential of biologic therapies by avoiding unwanted immune responses, today … Continued
Natron Energy’s Unique Cell Chemistry Shines in Collaborative Study with Lawrence Berkeley Lab and New York University A collaboration between Natron Energy and scientists at the Department of Energy’s Lawrence Berkeley National Laboratory (Berkeley Lab) and New York University has … Continued
Twist Bioscience Expands North American Presence with Office in San Diego, California Twist Bioscience Corporation, a company enabling customers to succeed through its offering of high-quality synthetic DNA, today announced it has expanded its North American operations with a new … Continued
Inscripta Raises $55.5 Million to Advance Gene-Editing Technology Investment will grow company’s expert team, accelerate development and commercialization of gene-editing tools — including enzymes, reagents, instrumentation, and software Inscripta, a leading gene-editing technology company, today announced that it has closed … Continued
Cedars-Sinai and Emulate, Inc. Announce Patient-on-a-Chip Program Using Stem Cells and Organs-on-Chips Technology for Precision Medicine Scientists at Cedars-Sinai and Emulate, Inc.are pioneering a Patient-on-a-Chip program to help predict which disease treatments would be most effective based on a patient’s genetic makeup and … Continued
Emulate and Takeda Partner to Use Intestine-Chip for New Drug Target Identification and Validation in Drug Development for GI Diseases Emulate announced today that it has formed a strategic R&D collaboration with Takeda Pharmaceutical Company Limited to use Emulate’s Intestine-Chip … Continued